Intervention Review

You have free access to this content

Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia

  1. Magdolna Tardy1,*,
  2. Maximilian Huhn2,
  3. Rolf R Engel3,
  4. Stefan Leucht4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 3 AUG 2014

Assessed as up-to-date: 26 JAN 2011

DOI: 10.1002/14651858.CD009230.pub2


How to Cite

Tardy M, Huhn M, Engel RR, Leucht S. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD009230. DOI: 10.1002/14651858.CD009230.pub2.

Author Information

  1. 1

    Technische Universität München Klinikum rechts der Isar, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Germany

  2. 2

    Universitätsklinikum der Technischen Universität München, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Bavaria, Germany

  3. 3

    Ludwig-Maximilians-University Munich, Psychiatric Hospital, Muenchen, Germany

  4. 4

    Technische Universität München, Department of Psychiatry and Psychotherapy, München, Germany

*Magdolna Tardy, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Möhlstr. 26, München, 81675, Germany. magdolnatardy@yahoo.de. tmaggie78@googlemail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 3 AUG 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Childers 1964 {published data only}
Clark 1971 {published data only}
  • Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25(5):404-9.
Cole 1964 {published data only}
  • National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10(3):246-61.
Galbrecht 1968 {published data only}
Hanlon 1965 {published data only}
Lasky 1962 {published data only}
  • Lasky JJ, Klett CJ, Caffey EM, Bennett JL, Rosenblum MP, Hollister LE. Drug treatment of schizophrenic patients. A comparative evaluation of chlorpromazine, chloprothixene, fluphenazine, reserpine, thioridazine and triflupromazine. Diseases of the Nervous System 1962;23(12):698-706.
NIMH 1967 {published data only}
  • National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Differences in clinical effects of three phenothiazines in "acute" schizophrenia. Diseases of the Nervous System 1967;28(6):369-83.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Cesarec 1974 {published data only}
  • Cesarec Z, Eberhard G, Nordgren L. A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. A clinical and experimental-psychological study. Acta Psychiatrica Scandinavica Supplementum 1974;249:65-77.
Chacon 1973 {published data only}
Galdi 1988 {published data only}
  • Galdi J, Bonato RR. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie] 1988;33(9):816-8.
Gunby 1968 {published data only}
  • Gunby B, Brun H, Hartviksen I. Fluphenazine in the long term treatment of psychoses. A preliminary communication. Acta Psychiatrica Scandinavica Supplementum 1968;203:225-30.
Hordern 1964 {published data only}
Kane 1983 {published data only}
  • Kane JM. Low dose medication strategies in the maintenance treatment of schizophrenia. Schizophrenia Bulletin 1983;9(4):528-32.
  • Kane JM, Rifkin A, Woerner M, Reardon G. Low-dose neuroleptics in outpatient schizophrenics. Psychopharmacology Bulletin 1982;18(1):20-1.
  • Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, et al. High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacology Bulletin 1985;21(3):533-7.
  • Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry 1983;40(8):893-6.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Altman 1996
  • Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
Andreasen 2010
  • Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic drug equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010;67:255-62.
Berger 2003
  • Berger M. Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban & Fischer, 2003.
Bland 1997
  • Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
Campbell 2000
  • Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy 2000;5:12-6.
Carpenter 1994
David 2004
  • David A, Adams Clive E, Eisenbruch M, Quraishi Seema N, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2004, issue 2. [DOI: 10.1002/14651858.CD000307; CD000307]
Davis 1974
Davis 1989
  • Davis JM, Barter JT, Kane JM. Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Baltimore, MD: Williams and Wilkins, 1989.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town, 2000.
Der-Simonian 1986
Divine 1992
Dold 2012
  • Dold M, Li C, Tardy M, Leucht S. Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009831]
Egger 1997
  • Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
Falkai 2005
  • Falkai P, Wobrock T, Lieberman J. World Federation of Societies of Biological Psychiatry (WFSBP)-Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 2005;6:132-91.
Furukawa 2011
  • Furukawa TA, Akechi T, Wagenpfeil S, Leucht S. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research 2011;126:212-9.
Gaebel 2006
  • Gaebel W, Falkai P, Weinmann S. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006.
Gulliford 1999
  • Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Guy 1976
  • Guy W. Clinical Global Impressions Scale. ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). National Institute of Mental Health, 1976.
Haase 1983
  • Haase HJ. Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch-Verlagsgesellschaft, 1983.
Higgins 2008b
  • Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jones 2006
  • Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia-cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-86.
Kane 2011
  • Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Journal of Clinical Psychiatry 2011;72(3):349-55.
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
Klein 1969
  • Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, MD: Williams and Wilkins, 1969.
Lehman 2004
  • Lehman AF, Lieberman JA, Dixon LB. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161:1-56.
Leucht 2005a
Leucht 2005b
Leucht 2009
Leucht 2009b
Lieberman 2005
Lohse 2005
  • Lohse MJ, Lorenzen A, Müller-Oerlinghausen B. Psychotropic drugs [Psychopharmaka]. Arzneimittel Verordnungs Report 2005:820-64.
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Marvaha 2004
Moher 2010
  • Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
Mothi 2013
Nolte 2004
  • Nolte S, Wong D, Latchford G, Boyle O, Anaenugwu A. Amphetamines for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2004, issue 3. [DOI: 10.1002/14651858.CD004964; CD004964]
Overall 1962
  • Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-12.
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org.
Seeman 1975
Tardy 2011
  • Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009227; CD009227]
Tardy 2011b
  • Tardy M, Leucht S, Potapov A, Kissling W, Engel R, Huhn M, et al. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009268; CD009268]
Tardy 2011c
  • Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009369; CD009369]
Tardy 2011d
  • Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Trifluoperazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009396; CD009396]
Tsuang 1978
  • Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.